The Chronic Thromboembolic Pulmonary Hypertension drugs in development market research report provides comprehensive information on the therapeutics under development for Chronic Thromboembolic Pulmonary Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Chronic Thromboembolic Pulmonary Hypertension. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Chronic Thromboembolic Pulmonary Hypertension and features dormant and discontinued products.
GlobalData tracks six drugs in development for Chronic Thromboembolic Pulmonary Hypertension by five companies/universities/institutes. The top development phase for Chronic Thromboembolic Pulmonary Hypertension is phase i with two drugs in that stage. The Chronic Thromboembolic Pulmonary Hypertension pipeline has six drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Chronic Thromboembolic Pulmonary Hypertension pipeline products market are: Bayer, Daiichi Sankyo and Pharmosa Biopharm.
The key targets in the Chronic Thromboembolic Pulmonary Hypertension pipeline products market include Soluble Guanylate Cyclase (sGC or EC 4.6.1.2), Prostacyclin Receptor (Prostaglandin I2 Receptor or Prostanoid IP Receptor or PTGIR), and Coagulation Factor X (Stuart Prower Factor or Stuart Factor or F10 or EC 3.4.21.6).
The key mechanisms of action in the Chronic Thromboembolic Pulmonary Hypertension pipeline product include Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) Activator with two drugs in Phase II. The Chronic Thromboembolic Pulmonary Hypertension pipeline products include two routes of administration with the top ROA being Oral and one key molecule types in the Chronic Thromboembolic Pulmonary Hypertension pipeline products market including Small Molecule.
Chronic Thromboembolic Pulmonary Hypertension overview
Chronic thromboembolic pulmonary hypertension (CTEPH) also called as Chronic pulmonary embolism, is a pulmonary vascular disease caused by chronic block of the major lung arteries. It is the major cause of chronic PH leading to right heart failure and death.
For a complete picture of Chronic Thromboembolic Pulmonary Hypertension’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
